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Introduction: The invariant natural killer T (iNKT) cell has been shown to play a central role in early stages immune
responses against Mycobacterium tuberculosis (Mtb) infection, which become nonresponsive (anergic) and fails to
control the growth of Mtb in patients with active tuberculosis. Enhancement of iNKT cell responses to Mtb antigens
can help to resist infection.
Study design and methods: In the present study, an Mtb 38-kDa antigen-specific T cell receptor (TCR) was isolated
from human CD8+ T cells stimulated by 38-kDa antigen in vitro, and then transduced into primary iNKT cells by
retrovirus vector.
Results: The TCR gene-modified iNKT cells are endowed with new features to behave as a conventional MHC class
I restricted CD8+ T lymphocyte by displaying specific antigen recognition and anti-Mtb antigen activity in vitro. At
the same time, the engineered iNKT cells retaining its original capacity to be stimulated proliferation by non-protein
antigens α-Gal-Cer.
Conclusions: This work is the first attempt to engineer iNKT cells by exogenous TCR genes and demonstrated that
iNKT cell, as well as CD4+ and CD8+ T cells, can be genetically engineered to confer them a defined and alternative
specificity, which provides new insights into TCR gene therapy for tuberculosis patients, especially those infected
with drug-resistant Mtb.
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Mycobacterium tuberculosis (Mtb) is an intracellular
bacterium that can be systemically cleared following a
coordinated response between the innate and adaptive
arms of the immune system. Invariant natural killer T
(iNKT) cells, a sublineage of T lymphocytes with features
of both T and natural killer (NK) cells, serve as a bridge
between innate and adaptive immunity [1], act as the first
line of defense against Mtb infectious. The iNKT cell
number and interferon gamma (IFN-γ) production have
been shown to peak as early as at 7 days post-Mtb in-
fection [2], 1 to 2 weeks before the development of the
MHC-restricted T cell response [3]. iNKT cells are* Correspondence: maryhmz@126.com
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unless otherwise stated.recruited to infected lungs and killed intracellular Mtb
either directly by granule-dependent mechanisms, or
indirectly by secreting IFN-γ and tumor necrosis factor
alpha (TNF-α) to activate infected macrophages [4,5].
Furthermore, iNKT cells were found to be indispens-
able at the earliest stage of granulomatous responses
for effectively restricting Mtb dissemination [6-8]. Thus,
iNKT cells have a central role in the early immune re-
sponses against Mtb infection. Although T cell receptors
(TCRs) gene transfer is a widely used, mature technology,
the successful development of TCR gene-modified iNKT
cells has not been reported.
Although the number of iNKT cells increased in le-
sions of virulent Mtb infected mice, they become anergic
and fail to control Mtb infection [9]. Additionally, the
iNKT cell levels in peripheral blood mononuclear cells
(PBMCs) of patients with chronic pulmonary Mtb infectionhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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healthy donors [10]. Therefore, enhancement antibacterial
activity of iNKT cells may be a promising strategy to sup-
press Mtb growth in the early stage of infection.
The emergences of multidrug-resistant strains and
extensively drug-resistant strains make it urgent to
designing immune therapeutic options to control TB
[11]. Immunotherapy tuberculosis (TB) based on iNKT
cells show great initial promise. Sada-Ovalle et al.
transferred iNKT cells into a virulent Mtb-infected
mouse model and found a significant reduction of pul-
monary Mtb burden [12]. TCRs express on the surface
of T lymphocytes that is responsible for recognizing
antigens. TCR gene transfer is an attractive and power-
ful strategy to generate a large number of effector cells
with high functional avidity in a short time [13]. Recently,
TCR gene engineered T cells have been developed for
adoptive cellular immune therapy of viral infectious dis-
eases [14,15] and cancer [16]. Rosenberg et al. adoptively
transferred engineered T cells carrying melanoma antigen-
specific TCR genes to melanoma patients and achieved
disease regression, demonstrating the potential clinical
application value of this approach [17]. Although TCR
gene transfer is widely used in conventional MHC class I
or II restricted CD4 or CD8 T lymphocyte, engineered
iNKT cells have never been reported.
Mtb 38-kDa antigen is one of the most immunogenic
Mtb antigens that can be either secreted or expressed on
the cell surface, evoking both prominent cellular and
humoral immune responses [18]. 38-kDa antigen strongly
polarized Th1 type immune response in vaccinated mice,
which act as Bacillus Calmette Guérin (BCG), leading to
significant reduction of bacterial load [19]. Furthermore,
38-kDa antigen has been used in the diagnosis of infection
by displays higher specificity than other Mtb antigens
[20,21].
The goal of this work was to engineer iNKT cells with
an exogenous Mtb peptide-specific TCR gene by retro-
virus transduction. Our work provides a foundation for
the application of TCR gene-modified iNKT cells for
future adoptive cellular immunotherapy of TB, especially
with drug-resistant Mtb infection.
Materials and methods
Isolation and culture of T cells and dendritic cells
Healthy fresh blood samples were obtained from a HLA-
A*2402+ healthy volunteer after obtaining written informed
consent. This protocol approved by the ethics committee
of Southern Medical University. PBMCs were isolated and
divided into several aliquots. The isolation procedure and
culture of T cells and dendritic cells (DCs) were per-
formed as previously described [22]. Monocytes were
positively selected using CD14+ magnetic bead (mini-
MACS, Miltenyi Biotec, Gladbach, Germany) and wereinduced to differentiate into dendritic cells (DCs) by
adding 500 U/mL interleukin-4 (IL-4) and 1000 U/mL
of granulocyte macrophage-colony stimulating factor
(GM-CSF; both from PeproTech, Rocky Hill, NJ, USA),
or into macrophages by adding 1000 U/mL of GM-CSF
in RPMI-1640 (Corning, NY, USA). Both cells were
cultured for 7 days and the medium was half-changed
every 3 days.
Stimulation of 38-kDa antigen-specific CD8+ T cell
On day 7 of DC culture, 10 μg/mL of the 38-kDa antigen
(ImmunoDiagnostics, Woburn, MA, USA) and 20 ng/mL
TNF-α were added. After 24 h the antigen-loaded DCs
were cocultured with autologous CD8+ T cells sorting
from PBMCs by CD8+ magnetic bead (miniMACS) at a
responder to stimulator ratio of 10:1. The medium supple-
mented with 100 U/mL of IL-2 was half-changed on day
3. Such stimulation was repeated twice at 7-day intervals.
TCR analysis of 38-kDa antigen-specific CD8+ T cell
To determine the TCR α and β chains of the 38-kDa
antigen-specific CD8+ T cell, GeneScan analysis of TCR
complementarity determining region 3 (CDR3) spectra-
typing was performed as previously described [23]. CD8+ T
cells stimulated by 38-kDa antigen were immediately
lysed. The RNA was extracted using the E.Z.N.A.® Total
RNA Kit (OMEGA Bio-tek, Inc., Norcross, GA) and re-
verse transcription was performed using the RevertAid™
First Strand cDNA Synthesis Kit (Fermentas, Life
Sciences, Ontario, Canada) according to the manufac-
tures’ instruction.
CDR3 analysis within the TCR α chain was performed
by PCR amplification each of the 32 human TCR AV
gene families, and the TCR β chain was performed by
amplification of 24 BV gene families. These were carried
out in a volume of 25 μl containing 1 μl each of the
forward AV or BV primer and the reverse AC-FAM or
BC-FAM primer, 1 mM MgCl2, 5 mM Tris–HCl,
100 mM of each dNTP, and 0.5 μl of cDNA. PCR ampli-
fication for TCR α chain was carried out with 35 cycles
of denaturing at 95°C for 30 s, annealing at 60°C for 30s,
and extension at 72°C for 30 s, and amplification for β
chain was carried out with 35 cycles of denaturing at 94°C
for 30 s, annealing at 55°C for 30s, and extension at 72°C
for 30 s. Two μl Fluorescent PCR products mixed with
2 μl of formamide, 0.5 μl of loading dye (25 mM EDTA,
50 ng/ml blue dextran), 0.5 μl of GeneScan-500 TAMRA
dye-labeled size standards, the mixture was denatured at
95°C for 2 min, and 2 μl was loaded onto the gel (6%
acrylamide, 6 M urea sequencing gel) and run for 2 h on
373A DNA sequencer (Applied Biosystems, USA), DNA
products of the appropriate lengths were analyzed using
GeneScan software version 672. The relative fluorescence
intensity (RI) was measured as: RI = 100 × (clonal peak
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to determine whether a given TCR AV or BV family was
monoclonal proliferation: a single peak with an RI%
greater than 35% [24].
Generation of mutated TCRs
According to the monoclonal expansion antigen specific
CD8+ TCR gene families identified by GeneScan ana-
lysis, primers were designed to amplify the full-length
TCR α9 (Accession No.: NG_001332.2) and β5 (Accession
No.: NG_001333.2) coding sequences incorporating the
nine amino acid-mutated C regions using overlapping
PCR methods [25]. The β5-chain V region (and a portion
of the C region) was amplified with the β5 forward primer
P1 5’-CCGGAATTCATGGGCTCCAGGCTGCTCTGTT
GGGTGCTGCTTTG-3’ and the reverse primer P2 5’-C
TTGTTCAGGTCCTCTACAACTGTGAGTCTGGTGC
CTTGT-3’. Amplification of the mutated C regions (and a
portion of the V region) were performed with the forward
primer P3 5’-AGACTCACAGTTGTAGAGGACCTGA
ACAAGGTGTTCCCA C-3’ and the reverse primer P4
[containing 5’-end of P2A [26].] 5’-CTTCCACGTCTC
CTGCTTGCTTTAACAGAGAGAAGTTCGTGGCTCC
GGAGCCGAATCCTTTCTCTTGACCATGGCCAT-3’.
A second PCR using the primers P1 and P4 completed
the β5-chain. Similarly, the α9-chain was generated with
the following primers: the α9 forward primer P5 (contain-
ing 3’-end of P2A) 5’-CGAACTTCTCTCTGTTAAAGCA
AGCAGGAGACGTGGAAGAAAACCCCGGTCCCATG
TGGGGAGCTTTCCTTCTCTATGT-3’ with the reverse
primer P6 5’-GTCAGGGTTCTGGATATTTGCAATCA
CAGAAAGTCTTGTG-3’, the forward primer P7 5’-
TCTGTGATTGCAAATATCCAGAACCCTGACCCTGC
CGTGT-3’ with the reverse primer P8 5’-CCGCTCG
AGTCAGCTGGACCACAGCCGCAGCGTCATGAGCA
G-3’. The α9-chain was completed with the primers P5
and P8.
Subsequently, a third PCR using the primers P1 and
P8 completed the full-length TCR β5/α9 in which the
two TCR chains were linked with the P2A peptide se-
quence. The PCR products were digested with BamH-I
and Xho-I (TaKaRa, Japan) and inserted into the pMX-
internal ribosomal entry site (IRES)-green fluorescent
protein (GFP) retroviral vector (kindly provided by Han
H, Fourth Military Medical University, Xi’an, China).
Construction of recombinant retroviral vector
To prevent mispairing of the exogenous and endogenous
TCR, α9 and β5 chains contain 9 amino acid-mutated C
regions amplify by the above overlapping PCR methods
have been connected by 2A and inserted into the retro-
virus empty vector PMX-IRES-GFP. Construction of the
recombinant retroviral vector was performed as previously
described [25]. Retrovirus was packaged by co-transfectionof the recombinant vector pMX-β5-2A-α9 and the VSV-G
envelope protein vector into the retroviral packaging cell
line GP2-293 with Lipofectamine 2000 Transduction Re-
agent (Invitrogen, Carlsbad, CA, USA) following manufac-
turer’s instructions and concentrated and the virus titer
was determined as described before [25].
Culture and isolation of iNKT cells
One aliquot of PBMCs was inoculated in 24-well plates
(Nunc, Roskilde, Demark) at 2 × 106/well in RPMI-1640
medium (Hyclone Ltd, Logan, UT) containing 10% fetal
bovine serum (FBS; Hyclone), 100 ng/mL α-GalCer
(Kirin Brewery, Gunma, Japan) and 10 ng/mL IL-2
(PeproTech, Rocky Hill, NJ, USA) for 7 days. For enrich-
ment and expansion of iNKT cells, the culture of an-
other aliquot of PBMCs (used as autologous APCs) was
supplemented with 500 U/mL IL-4 and 1000 U/mL
GM-CSF for 7 d and pulsed with 100 ng/mL a-GalCer
and 20 ng/mL TNF-α(PeproTech, Rocky Hill, NJ, USA)
for 24 h, and then added at 7-d interval into the iNKT
culture. Medium was half-changed every 2–3 days. After
the second stimulation, iNKT cells were positively se-
lected using Vα24+ TCR magnetic bead (miniMACS,
Miltenyi Biotec, Gladbach, Germany).
Transduction of iNKT cells
iNKT cells (1 × 106 cells/mL) were seeded in the presence
of 10 ng/mL IL-2 and 50 ng/mL anti-human CD3/CD28
Dynabeads (Invitrogen) 48 h prior to transduction. The
concentrated retroviral supernatant containing 8 μg/mL
of polybrene (Sigma, St Louis, MO, USA) was added and
4 h later the same fresh medium was supplemented to di-
lute the polybrene to 2 mg/mL. Five days after transduc-
tion, cells were collected and labeled with anti-TCR Vβ5
antibody to assess the transduction efficiency and the ex-
pression of exogenous TCR Vβ5 by Flow cytometry.
Immunofluorescence
Transduced or untransduced iNKT cells (1 × 106) were
stained with the following antibodies using the method
described before [22]: phycoerythrin (PE)-TCR Vα24
(clone 6B11, Miltenyi Biotec), allophycocyanin (APC)-
TCR Vβ5 (Immudex), APC- or PE-labeled IgG1 (Becton
Dickinson Pharmingen, San Jose, CA, USA). Expression of
exogenous genes was observed using a confocal laser
scanning microscope (FV1000, Olympus, Tokyo, Japan)
and quantified by Flow cytometry on a FACSCalibur flow
cytometer using CELLQuest software (Becton Dickinson).
Intracellular Flow was used to further detail the iNKT
cell populations expressed cytokines upon activated by
Mtb antigen 38-kDa stimulation. TCR gene-modified
iNKT cells were stimulated by 38-kDa antigen-loaded
DCs (E/T = 20). After 24 h, 1 × 106 of cocultured cells
were centrifugated at 2000 rpm for 5 min and washed
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BD Cytofix/Cytoperm™ Fixation/Permeabilization Solu-
tion Kit (BD Pharmingen Company, San Jose, CA, USA)
and stained by BD FastImmune fluorescein isothiocyanate
(FITC) -labeled Anti-IFN-γ antibody (Becton Dickinson,
San Diego, CA, USA) according to the instructions, ex-
pression of IFN-γ was detected by Flow cytometry.
Cell proliferation assays
Irradiated (30 Gy) DCs were cocultured at 5 × 103 cells/
well in triplicate with autologous iNKT cells in a 96-well
plate at an effector/target (E/T) ratio of 20:1. After
culturing for 1, 4, or 7 days, cell proliferation was mea-
sured using the Cell Counting Kit-8 (Dojindo, Kumamoto,
Japan) according to the instructions of manufacturers. The
absorbance was determined with a spectral scanning multi-
mode reader (Scientific Varioskan Flash, ThermoElectron,
San Jose, CA, USA).
Cytokine release assay
Antigen-loaded autologous DCs (5 × 103 cells/well) that
were irradiated at a dosage of 30 Gy were cocultured
with iNKT cells as stimulators in 96-well plates at the ra-
tios as indicated in the legends. Also at the indicated
time the culture supernatants were collected for assay of
IFN-γ, TNF-α, or granzyme B (GrB) release with ELISA
(Bender MedSystems, Vienna, Austria) as per the manu-
facturer’s instructions.
Cytotoxicity assays
Cytotoxicity assays were carried out using a DELFIA
EuTDA cytotoxicity kit (Perkin-Elmer Life Sciences,
Norwalk, CT, USA) according to the manufacturers’
instruction. Eu-labeled autologous DCs (5 × 103) were
co-cultured with TCR-transduced effector cells at an E/T
ratio of 30:1. After co-cultured 4 h, the specific lysis was de-
tected with the Varioskan Flash reader (ThermoElectron)
and calculated using the following formula: [(experimental
release - spontaneous release)/(maximum release -
spontaneous release)] × 100, where the maximum or the
spontaneous release were determined by detecting the
target cells incubated alone with or without complete
cytolysis.
Statistical analysis
One-way analysis of variance was used to test the
statistical significance. Welch correction was applied
for the unequal variance. Least significant difference
multiple comparison test or Dunnett’s T3 was used
to compare the means between groups. Two-sided
P-values < 0.05 were considered statistically signifi-
cant. Statistical analyses were performed using the
SPSS for windows statistical package version 17.0 (SPSS,
Chicago, IL, USA).Results
Screening for monoclonal expansion TCR gene families
The CDR3 spectratyping of almost all TCR Vα and Vβ
gene families of CD8+ T cells displayed a Gaussian distri-
bution of the expected polyclonal T cell populations
before stimulation. However, several families such as
TCR Vα9, Vα19 and Vβ5 showed abnormal distribution
characteristic of oligoclonal or monoclonal expansion
after stimulation. The TCR gene families showed a single
peak and RI% > 35% after stimulation indicated mono-
clonal expansion and specific to the Mtb 38-kDa anti-
gen, therefore the TCR Vα9 and Vβ5 gene families was
selected (Figure 1).
Retroviral vector construction
The sequences of full-length TCR β5 (927 bp) and α9
(810 bp) gene were shown in Figure 2A. The mutated
TCR β5 and α9 gene incorporating the nine amino
acid-mutated C regions was created using overlapping
PCR methods. Sequencing results showed no un-
desired mutation in the recombinant DNA fragment
(Data not shown). The recombinant retroviral vector
pMX-β5-P2A-α9-IRES-GFP was constructed by insert-
ing the full-length TCR gene β5-P2A-α9 (1821 bp)
into the empty vector PMX-IRES-GFP (Figure 2A),
and was then used to package the recombinant retro-
virus. According to Flow cytometry analysis, the retro-
virus titer was approximately 1.2 × 107 IU/mL (Data
not shown).
Efficient expansion and isolation of human iNKT cells
The percentage of iNKT cells in human PBMCs is ex-
tremely low (0.01% - 1%). Short-term in vitro culture to
obtain sufficient numbers of cells is indispensable for
iNKT cell studies. Under the microscope, iNKT cells in
human PBMCs cultured using whole PBMCs as APCs to
presented alpha-Gal-cer antigen showing obvious, bulky,
and numerous colonies in day 14 (Figure 3A). After
isolation by positive magnetic bead sorting, the purity of
Vα24+ iNKT cells determined by Flow cytometry was
achieved 96.78% (Figure 3B).
Expression of exogenous genes by TCR gene-modified
iNKT cells
For functional avidity, it is important that the expression
level of the transduced TCR gene be high on the recipi-
ent cell surface. Under fluorescence microscopy, the
APC fluorescence of TCR Vβ5 labeling was clearly ob-
served in TCR gene-modified iNKT cells (Td), but not
in untransduced (UnTd) and empty vector-transduced
(EmTd) iNKT cells, 5 d after transduction (Figure 3C).
Flow cytometry analysis demonstrated that 45.06% of TCR
gene-modified iNKT cells express both Vα24 and Vβ5. By
Figure 1 CDR3 spectratyping of CD8+ T cell TCR α and β chain genes before and after stimulation with the Mtb 38-kDa antigen. The polyclonal
Gaussian distribution of Vβ5 and Vα9 gene families (framed) before stimulation changed to a monoclonal proliferation peak after stimulation,
indicating their specificity to the Mtb 38-kDa antigen.
Figure 2 Schematic representation of the recombinant retroviral vector. (A) The sequence of wild type TCR β5 (the above panel) and α9 genes
(the below panel), and the structure diagram of recombinant retroviral vector pMX-β5-P2A-α9-IRES-GFP carrying the hybrid TCR β5 and α9 genes
with point mutations in the C regions (the middle panel). (B) The PCR results analyzed with 2% agarose gel showed the full-length genes of
hybrid β5-P2A-α9, β5 and α9 chains, respectively.
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Figure 3 Culture and transduction of human iNKT cells. (A) iNKT cells in PBMCs were expanded 300-folds after stimulation with α-GalCer for 14 d.
The upper panel: prominent cell colonies were observed (Magnification: 200×); the lower panel: the percentage of iNKT cells in PBMCs and the
purity of iNKT cells after isolation with microbeads. (B) The purity of iNKT cells before and after isolation with microbeads, (C) and the expression
of the PE-Vα24 (red) and APC-Vβ5 (blue) genes after retroviral transduction, were observed under fluorescence microscopy (D) and analyzed with
Flow cytometry. (E) Intracellular Flow cytometry analysis the iNKT cell populations expressed IFN-γ upon activated by Mtb antigen 38-kDa
stimulation. UnTd (untransduced iNKT cells); EmTd (empty vector-transduced iNKT cells); Td (TCR gene-modified iNKT cells). Td + 38-kDa
(TCR gene-modified iNKT cells + 38-kDa antigen-loaded DCs).
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cell controls have no Vβ5 expression (Figure 3D).
Antigen-specific proliferation of TCR-engineered iNKT cells
Significant proliferation was seen in TCR gene-modified
iNKT cells stimulated with 38-kDa loaded DCs (P < 0.001)
at days 4 and 7 after stimulation, suggesting that TCR
gene-modified iNKT cells proliferated rapidly upon 38-
kDa antigen stimulation. For the same engineered iNKT
cells, stimulation with unassociated antigen OVA and
Mtb-associated antigen ESAT-6 did not induce obvious
proliferation, similar to untransduced or empty vector-
transduced iNKT cells stimulated with 38-kDa antigen.
Obvious proliferation was also observed in engineered
iNKT cells stimulated by alpha-Gal-cer, demonstrated that
the engineered iNKT cells retaining its original capacity to
be stimulated proliferation by non-proteic antigens alpha-
Gal-Cer.
The proliferation response of TCR gene-modified
iNKT cells stimulated by 38-kDa can been blocked byboth anti-CD8 and anti-HLA Class I antibodies
(Figure 4A), demonstrated that TCR gene-modification
of iNKT cells can lead to highly specific proliferation
activity.
Antigen-specific IFN-γ, TNF-α, and GrB production in TCR
gene-modified iNKT cells
TCR gene-modified iNKT cells stimulated by 38-kDa
antigen-loaded DCs produced significantly higher
levels of cytokine IFN-γ (P < 0.001), TNF-α (P < 0.001),
and granzyme B (GrB; P < 0.001) than the similarly
stimulated negative controls (untransduced and empty
vector-transduced iNKT cells stimulated by 38-kDa
antigen-loaded DCs), Compared with non-specific
antigen controls (the TCR gene-modified iNKT cells
stimulated by OVA- and ESAT-6 loaded DCs), the
levels of IFN-γ (P < 0.001), TNF-α (P < 0.001), and GrB
(P < 0.001) expressed by the same type of effector cells
stimulated by 38-kDa antigen-loaded DCs were also
higher (Figure 4B).
Figure 4 (See legend on next page.)
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Figure 4 Proliferation, cytokine secretion and cytotoxicity of TCR gene-modified iNKT cells. (A) Proliferation of TCR gene-modified iNKT cells
co-cultured with antigen-loaded or -unloaded DCs. (B) INF-γ, TNF-α and GrB secretion of TCR gene-modified iNKT cells at different E:T ratios (left
panels) and time points (center panel). Compared with other control groups, TCR gene-modified iNKT cells exerted enhanced specific anti-TB
antigen activities and these activities can be block by anti-HLA and anti-CD8 antibody (right panels). (C) Cytolytic activity of exogenous TCR
gene-modified iNKT cells. UnTd + 38-kDa (untransduced iNKT cells + 38-kDa antigen-loaded DCs); EmTd + 38-kDa (empty vector- transduced iNKT
cells + 38-kDa antigen-loaded DCs); Td + α-Galcer (TCR gene-modified iNKT cells + α-Gal-cer-loaded DCs); Td + OVA (TCR gene-modified iNKT cells +
OVA-loaded DCs); Td + ESAT-6 (TCR gene-modified iNKT cells + ESAT-6 antigen -loaded DCs); Td + 38-kDa (TCR gene-modified iNKT cells + 38-kDa
antigen-loaded DCs). *P < 0.001 compared with UnTd + 38-kDa group.
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deed the responders, an assay of intracellular IFN-γ
staining have been performed on engineered iNKT cells
stimulated by 38-kDa antigen-loaded DCs, Flow cytome-
try results showing that 98.73% of IFN-γ producing cells
are exogenous TCR gene expressed iNKTcells (Figure 3E).
Moreover, when anti-HLA Class I or anti-CD8 antibodies
was added, the amounts of cytokines in the TCR gene-
modified iNKT cells stimulated by 38-kDa antigen-loaded
DCs were obviously decrease (Figure 4B), suggesting that
TCR gene-modified iNKT cells were endowed with func-
tional avidity in responded specifically to 38-kDa antigen
stimulation.
Antigen-specific cytolytic activity of TCR gene-modified
iNKT cells
Similar to the cytolytic activity of iNKT cells stimulated
by alpha-Gal-cer, TCR gene-modified iNKT cells co-
cultured with 38-kDa antigen-loaded DCs had a high
cytolytic activity. Almost 70% of 38-kDa antigen-loaded
DCs were specifically lysed by TCR gene-modified iNKT
cells at an E/T ratio of 30:1. By contrast, untransduced
and empty vector-transduced iNKT cells had only about
10% lytic activity, respectively. The lytic activity of TCR
gene-modified iNKT cells stimulated with 38-kDa anti-
gen was significantly higher than those stimulated with
OVA and ESAT-6 antigens (P < 0.001). Moreover, the
lytic activity of the TCR gene-modified iNKT cells re-
sponse to 38-kDa antigen-loaded DCs were obviously
decrease when anti-MHC Class I or anti-CD8 antibodies
was used to blocking the costimulatory signal of specific
recognize (Figure 4C), suggesting that TCR gene-modified
iNKT cells were endowed with specifically lysed avidity.
Discussion
Although current pharmacotherapy is effective against
susceptible Mtb strains, the emergence of multidrug and
extensively drug-resistant strains [27] requires the design
of new therapeutic options to enhance immune re-
sponse. iNKT cells are involved in various immune reac-
tions in early TB infection, such as regulation of innate
and acquired immune responses [3,28]. However, it was
reported that the number and function of iNKT cell se-
lectively reduced in PBMCs of pulmonary TB patients,and increased to the pre-infection level following effect-
ive treatments and disease remission [29,30]. Consistent
with other impaired immune responses in active pul-
monary TB patients, iNKT cell deficiency may contrib-
ute to Mtb replication and diffusion [31]. In this pilot
study, we established TCR gene-modified iNKT cells that
specifically recognized Mtb antigenic, and displayed in-
creased functional avidity compared with unmodified
iNKT cells.
TCR gene transfer is an attractive strategy to obtain
antigen-specific effector cells in a short time. However,
a likely difficulty with this approach is the potential
mismatch of endogenous and exogenous TCR genes:
that is to say, the introduced α or β chains may be mis-
paired with the endogenous α or β chains. As a result
of this situation, both the expression and the function
of the exogenous Mtb antigen-specific TCR genes on
the recipient cell surface will be decreased. To
minimize the likelihood of gene mismatch and to
enhance the stability of the exogenous TCRs, we intro-
duced several mutations into the TCR genes. Nine
amino acids in the C regions of the exogenous α and β
chains were substituted with their homologous coun-
terparts in the murine sequence [32]. A P2A ribosomal
skip element was used to link the exogenous α and β
chain genes to achieve equimolar expression [26]. Ex-
ogenous genes constructed by these stactics were
expressed normally, which is consistent with previous
reports [33].
Human iNKT cells express an invariant Vα24Jα18/
Vβ11 TCR that only recognizes glycolipid antigens in
conjunction with the CD1d molecule [34]. Genetic en-
gineering with HLA-restricted TCRs endows iNKT cells
with the specific recognition of the antigenic presented
by autologous or allogeneic APCs, one feature of the
adaptive immune system. Thus, to avoid cell rejection,
the prospective iNKT-based adoptive immunotherapy
must be restricted to TB patients who are HLA-
matching with the iNKT cells. In this study, the HLA
type HLA-A*2402 was chosen for its highest proportion
(>50%) in the Chinese population. Despite the HLA re-
strictions in adoptive immunotherapy, this TCR gene
transfer strategy can be widely used in any condition of
HLA restriction.
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autologous DCs, TCR gene-modified iNKT cells specific-
ally killed Mtb antigen-loaded target cells directly by
granule-dependent mechanisms, and simultaneously ex-
hibited an enhanced regulating function in the early
exposure of the Mtb antigen peptide through cytokine
secretion. Further studies should evaluate the efficacy of
TCR gene-modified iNKT cells in Mtb-infected animal
models. The iNKT cells transferred through tail vein in-
jection should move into the infected lung through
chemotaxis, via the interaction between CCR4 on the
iNKT cells and thymus- and activation-regulated chemo-
kines [35]. This process would greatly enhance the possi-
bility of the recognition between the iNKT cells and the
infected target cells.
Conclusions
We modified human iNKT cells by transduction with a
recombinant retrovirus carrying Mtb antigen-specific
TCR genes. The TCR genes were successfully expressed
on the iNKT cell surface and endowed the modified cells
with significantly enhanced anti-Mtb antigen activity. To
the best of our knowledge, this is the first attempt to
engineer iNKT cells by exogenous TCR genes. By intro-
ducing TCR gene-modified iNKT cells, our results pro-
vide new insights into TCR gene therapy and lay a basis
for future adoptive immunotherapy designed to prevent
or treat drug-resistant TB, particularly in immunocom-
promised persons.
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